MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.40
+0.02
+0.37%
Closed 16:00 08/12 EDT
OPEN
5.40
PREV CLOSE
5.38
HIGH
5.51
LOW
5.26
VOLUME
225.84K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
2.693
MARKET CAP
146.50M
P/E (TTM)
-1.5426
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CFRX stock price target is 15.67 with a high estimate of 22.00 and a low estimate of 8.00.

EPS

CFRX News

More
ContraFect secures funding of up to $18.9M
ContraFect announces (NASDAQ:CFRX) has announced up to $18.9M in additional non-dilutive investment from that CARB-X, to progress its second product candid
seekingalpha · 07/20 17:21
NVAX, NBL among premarket gainers
Seeking Alpha - Article · 07/20 12:29
ContraFect Announces Up To $18.9M In Funding From CARB-X To Support Acceleration Of CF-370 Program For Treating Pseudomonas Aeruginosa Infections Towards Clinical Stage Development
Benzinga · 07/20 11:35
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
YONKERS, N.Y., July 20, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
GlobeNewswire · 07/20 11:30
How Much Are ContraFect Corporation (NASDAQ:CFRX) Insiders Spending On Buying Shares?
Simply Wall St. · 07/03 13:48
2 Strong Buy Small-Cap Stocks That Could See Outsized Gains
TipRanks · 06/18 15:56
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
GlobeNewswire · 06/17 12:30
Contrafect Highlights Publication Of Exebacase Phase 2 Study Results In Journal Of Clinical Investigation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase 2 study results
Benzinga · 06/17 11:34

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About CFRX

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
More

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.